By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Aegera Therapeutics Inc. 

810 chemin du Golf

Ile des Soeurs (Montreal)  Quebec  H3E 1A8   Canada
Phone: 514-288-5532 Fax: 514-288-9280



Company News
Pharmascience Inc. Acquires Aegera Therapeutics; Aegera's Employees to Retain Their Jobs 5/27/2011 6:35:25 AM
Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma 1/26/2010 9:45:13 AM
Human Genome Sciences, Inc. (HGSI) and Aegera Therapeutics Announce Initiation of Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Lymphoid Tumors 11/23/2009 10:04:55 AM
Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 11/19/2009 8:52:38 AM
Aegera Therapeutics Announces Additional Lomitapide (AEGR-733) Phase III Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Safety Profile 11/16/2009 8:52:53 AM
Aegera Therapeutics Closes CDN $7 Million Financing 9/23/2009 10:57:37 AM
Aegera Therapeutics Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain 5/6/2009 11:32:55 AM
Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer 1/8/2009 10:33:48 AM
Aegera Therapeutics Phase 1/2 Clinical Trial Results Selected for Oral Presentation at 2008 American Society of Hematology Annual Meeting 11/25/2008 9:29:39 AM
Neurologix, Inc. Licenses Exclusive Rights to Key Gene from Aegera Therapeutics for Use as a Potential Gene Therapy for Huntington's Disease 9/3/2008 6:06:48 AM